Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,719.02
-6.5424-0.38%
Number of Gainers:- -
Number of Losers:2
Number of Flat:- -
PE:- -
High:1,742.20
Open:1,728.53
Low:1,717.08
Close:1,725.57
Volume:7.52M
Turnover:1.07B
Market Cap:443.02B
Float Cap:434.81B

Loading ...

Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials

TIPRANKS
·
Sep 01

Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement

TradingKey
·
Sep 01

Novartis's Multiple Sclerosis Trial Results Match Best Hopes

Dow Jones
·
Sep 01

US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy

Stock News
·
Sep 01

Novartis up Nearly 6%, on Pace for Largest Percent Increase Since March 2023

Dow Jones
·
Sep 01

【US Pre-Market】US Futures and Chip Stocks Fall as Global Bond Sell-Off Deepens; Gold Drops Below $4,400, Brent Crude Tops $92

TradingKey
·
Sep 01

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

Why Novartis Stock is Heading for Its Best Day Since 2023 After 3 Patient Deaths

Dow Jones
·
Sep 01

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Dow Jones
·
Sep 01

Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib

TIPRANKS
·
Sep 01

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

TIPRANKS
·
Sep 01

Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials

MT Newswires Live
·
Sep 01

Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise

Stock News
·
Sep 01

Novartis Pauses Autoimmune Cell Therapy Studies After Deaths

Dow Jones
·
Sep 01

Novartis AG Falls Monday, Outperforms Market

Dow Jones
·
Sep 01

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.
·
Aug 30

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo

TIPRANKS
·
Aug 29

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Reuters
·
Aug 28

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Reuters
·
Aug 28